Cite
HARVARD Citation
Rossotti, R. et al. (2020). Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts. Digestive and liver disease. 52 (4), pp. 447-451. [Online].